Abstract Background: Ovarian epithelial cancer is a dreadful gynecologic malignancy, with a usual late diagnosis and humble therapy response. EpCAM over-expression in epithelial ovarian cancer could be considered as a hopeful cancer target therapy. Aim of Study: Detection of EpCAM over-expression in ovarian cancer and correlate it with the clinic-pathological tumor features. Material and Methods: 42 paraffin blocks of ovarian cancer were immunostained with EpCAM antibody. Results: EpCAM showed high expression in 54.7% of the studied cases, and it was significantly correlated with the patients' age, tumor size, tumor grade, the presence of lym-phovascular emboli, extension to the serosal surface, and FIGO stage. Conclusion: EpCAM is overexpressed in epithelial ovarian cancer, which could be a future target therapy.
MOHAMED S. NEGM, M.D., R. R. M. M., & I. AMER, M.D., S. (2022). EpCAM Expression in Epithelial Ovarian Cancer: Immunohistochemical and Histopathological Study. The Medical Journal of Cairo University, 90(3), 113-119. doi: 10.21608/mjcu.2022.234835
MLA
RASHA R. MOSTAFA, M.D.; MOHAMED S. NEGM, M.D.; SAMAR I. AMER, M.D.. "EpCAM Expression in Epithelial Ovarian Cancer: Immunohistochemical and Histopathological Study". The Medical Journal of Cairo University, 90, 3, 2022, 113-119. doi: 10.21608/mjcu.2022.234835
HARVARD
MOHAMED S. NEGM, M.D., R. R. M. M., I. AMER, M.D., S. (2022). 'EpCAM Expression in Epithelial Ovarian Cancer: Immunohistochemical and Histopathological Study', The Medical Journal of Cairo University, 90(3), pp. 113-119. doi: 10.21608/mjcu.2022.234835
VANCOUVER
MOHAMED S. NEGM, M.D., R. R. M. M., I. AMER, M.D., S. EpCAM Expression in Epithelial Ovarian Cancer: Immunohistochemical and Histopathological Study. The Medical Journal of Cairo University, 2022; 90(3): 113-119. doi: 10.21608/mjcu.2022.234835
)
View on SCiNiTO